07:00 , Oct 6, 2014 |  BC Week In Review  |  Company News

Shionogi sales and marketing update

Shionogi's C&O Pharmaceutical Technology (Holdings) Ltd. subsidiary launched rabeprazole sodium for injection in China to treat peptic ulcers. The company said the proton-pump inhibitor (PPI) is the only injectable rabeprazole product approved in China. The...
07:00 , Oct 24, 2011 |  BC Week In Review  |  Company News

C&O Pharmaceutical Technology (Holdings) Ltd., Shionogi deal

Shionogi completed the acquisition of about 42% of C&O, or 277.5 million shares, for S$0.50 per share, or about S$138.8 million ($109.6 million). Shionogi now owns 66% of C&O after acquiring 24% of the company...
07:00 , Sep 5, 2011 |  BC Week In Review  |  Company News

C&O, Shionogi deal

C&O Pharmaceutical Technology (Holdings) Ltd. (SGX:33963), Hong Kong, China   Shionogi & Co. Ltd. (Tokyo:4507; Osaka:4507), Osaka, Japan   Business: Pharmaceuticals   Shionogi began a general offer to acquire about 42% of C&O, or 277.5...
07:00 , Aug 29, 2011 |  BC Week In Review  |  Company News

C&O Pharmaceutical Technology (Holdings) Ltd., Shionogi deal

Shionogi completed the acquisition of about 24% of C&O, or 160.3 million shares. Shionogi, which will now acquire enough of C&O to make the company a subsidiary through a general offer, previously said it would...
07:00 , Aug 8, 2011 |  BC Week In Review  |  Company News

C&O, Shionogi deal

Shionogi said it will acquire a controlling interest of pharma C&O Pharmaceutical for about ¥14.3 billion ($184.5 million). Shionogi said the deal will expand its portfolio in China. At March 31, C&O reported nine-month revenues...
23:46 , Aug 1, 2011 |  BC Extra  |  Company News

Shionogi to acquire Chinese pharma

Shionogi & Co. Ltd. (Tokyo:4507; Osaka:4507) announced plans Monday to acquire Chinese pharma C&O Pharmaceutical Technology (Holdings) Ltd. (SGX:33963) for about Y14.3 billion ($184.5 million). Shionogi said the deal will expand its portfolio in China....